Stock Traders Buy High Volume of Celgene Corp. Call Options (CELG)
Celgene Corp. (NASDAQ:CELG) was the target of some unusual options trading activity on Monday. Traders purchased 26,795 call options on the stock, StockRatingsNetwork.com reports. This represents an increase of 291% compared to the average daily volume of 6,854 call options.
A number of analysts have recently weighed in on CELG shares. Analysts at Barclays raised their price target on shares of Celgene Corp. from $173.00 to $182.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Nomura initiated coverage on shares of Celgene Corp. in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at UBS AG downgraded shares of Celgene Corp. from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, three have given a hold rating and twenty-two have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $163.44.
Shares of Celgene Corp. (NASDAQ:CELG) traded down 2.89% on Monday, hitting $164.90. 7,857,161 shares of the company’s stock traded hands. Celgene Corp. has a 52 week low of $95.37 and a 52 week high of $173.80. The stock has a 50-day moving average of $165.7 and a 200-day moving average of $149.2. The company has a market cap of $67.950 billion and a price-to-earnings ratio of 48.89.
Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $6.00 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.